• 1
    Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:26752686.
  • 2
    zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131156.
  • 3
    IARC Monograph Working Group. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 90: Human Papillomaviruses. Lyon, France; IARC; 2007:1670.
  • 4
    Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet. 1987;1:12471249.
  • 5
    Anttila A, Laara E. Cervix cancer: geographical correlations. In: Sankila R, Demaret E, Hakama M, Lynge E, Shouten LJ, Parkin EM, eds. Evaluation and Monitoring of Screening Programmes. Brussels, Belgium: Europe Against Cancer Programme; 2000:7797.
  • 6
    Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45:26402648.
  • 7
    Stoler MH, Schiffman MA. Interobserver reproducibility of cervical cytologic and histologic interpretations. JAMA. 2001;285:15001505.
  • 8
    Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252258.
  • 9
    Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727735.
  • 10
    Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer. 2009;125:24892496.
  • 11
    Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008;19:342354.
  • 12
    Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346355.
  • 13
    Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions [serial online]. Cochrane Database Syst Rev. 2013;(3):CD008054.
  • 14
    Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results. A meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009;13:648659.
  • 15
    Lorincz AT. Hybrid capture. Clin Chem. 1998;44:13631363.
  • 16
    Solomon D, Schiffman MA, Tarone B. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293299.
  • 17
    Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280293.
  • 18
    Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(suppl 3):S78S89.
  • 19
    Arbyn M, Ronco G, Anttila A, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine. 2012;30(suppl 5):F88F99.
  • 20
    ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:13931400.
  • 21
    Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525541.
  • 22
    Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(suppl 5):F55F70.
  • 23
    Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer. 2002;94:21992210.
  • 24
    Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring. J Med Virol. 2004;73:6570.
  • 25
    de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:10481056.
  • 26
    Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA HPV assay. J Clin Virol. 2009;45(suppl 1):S39S47.
  • 27
    Narimatsu R, Patterson BK. High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am J Clin Pathol. 2005;123:716723.
  • 28
    Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol Oncol. 2011;120:8993.
  • 29
    Shen Y, Gong J, He Y, Cheng G, Okunieff P, Li X. Quantivirus HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test. J Virol Methods. 2012;187:288293.
  • 30
    Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the Hybrid Capture II test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132:101108.
  • 31
    Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:21142119.
  • 32
    The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. National Cancer Institute Workshop. JAMA. 1989;262:931934.
  • 33
    Evans DM, Hudson EA, Brown CL, et al. Terminology in gynaecological cytopathology: report of the Working Party of the British Society for Clinical Cytology. J Clin Pathol. 1986;39:933944.
  • 34
    Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529536.
  • 35
    Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics. 2007;8:239251.
  • 36
    Harbord RM, Whiting P. Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J. 2009;9:211229.
  • 37
    Takwoingi Y, Diagnostic Test Accuracy Working Group. METADAS: an SAS macro for meta-analysis of diagnostic accuracy studies. Available at: [Accessed June 10, 2013.]
  • 38
    Diagnostic Test Accuracy Working Group. Handbook for Diagnostic Test Accuracy Reviews. Available at: [Accessed June 10, 2013.]
  • 39
    Andersson S, Hansson B, Norman I, et al. Expression of E6/E7 mRNA from “high risk” human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol. 2006;29:705711.
  • 40
    Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;17:30333043.
  • 41
    Halfon P, Benmoura D, Agostini A, et al. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol. 2010;47:177181.
  • 42
    Andersson E, Karrberg C, Radberg T, et al. Type-specific HPV E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia. J Clin Microbiol. 2011;49:37943799.
  • 43
    Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49:557564.
  • 44
    Szarewski A, Mesher D, Cadman L, et al. A comparison of 7 tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012;50:18671873.
  • 45
    Molden T, Nygard JF, Kraus I, et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer. 2005;114:973976.
  • 46
    Koliopoulos G, Chrelias C, Pappas A, et al. The diagnostic accuracy of 2 methods for E6&7 mRNA detection in women with minor cytological abnormalities. Acta Obstet Gynecol Scand. 2012;91:794801.
  • 47
    Alaghehbandan R, Fontaine D, Bentley J, et al. Performance of ProExC and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology [published online ahead of print January 22, 2013]. Diagn Cytopathol. 2013.
  • 48
    Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods. 2010;169:219222.
  • 49
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intra-epithelial or early invasive cervical lesions: a systematic review and meta-analysis of the literature. Lancet. 2006;367:489498.
  • 50
    Arbyn M, Kyrgiou M, Simoens C, et al. Peri-natal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: a meta-analysis [serial online]. BMJ. 2008;337:a1284.
  • 51
    ASCUS-LSIL Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized tria. J Natl Cancer Inst. 2000;92:397402.
  • 52
    Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010;48:27792785.
  • 53
    Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278285.
  • 54
    Nakagawa S, Yoshikawa H, Yasugi T, et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J Med Virol. 2000;62:251258.
  • 55
    Hovland S, Arbyn M, Lie AK, et al. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo. Br J Cancer. 2010;102:957965.
  • 56
    Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol. 2011;120:430438.
  • 57
    Tarkowski TA, Rajeevan MS, Lee DR, Unger ER. Improved detection of viral RNA isolated from liquid-based cytology samples. Mol Diagn. 2001;6:125130.
  • 58
    Pretorius RG, Kim RJ, Belinson JL, Elson P, Qiao YL. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis. 2006;10:59.
  • 59
    Roelens J, Reuschenbach M, von Knebel-Doeberitz M, Wentzensen N, Bergeron C, Arbyn M. p16INK4a immunocytochemistry versus HPV testing for triage of women with minor cytological abnormalities: a systematic review and meta-analysis. Cancer Cytopathol. 2012;120:294307.
  • 60
    Sanati S, Huettner P, Ylagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol. 2010;29:7987.
  • 61
    Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112:293299.
  • 62
    Varnai AD, Bollmann M, Bankfalvi A, et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 2008;19:457465.
  • 63
    Benevolo M, Terrenato I, Mottolese M, et al. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control. 2011;22:869875.
  • 64
    Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification. J Clin Microbiol. 2010;48:25242529.
  • 65
    Halfon P, Benmoura D, Agostini A, et al. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomarkers. 2010;7:133139.
  • 66
    Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res. 2011;17:24592465.
  • 67
    Rijkaart DC, Heideman DA, Coupe VM, et al. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol. 2012;50:23902396.
  • 68
    Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130:602610.